India covid-19 vaccine patient India

Covid-19 drugs and vaccines to drive Cadila Healthcare’s prospects

Reading now: 641
www.livemint.com

₹11,995/dose, with dispatches having started. Analysts at a domestic brokerage say the opportunity is huge and even if the company targets 1 crore patients, the size would be as large as their domestic business.In another development, Zydus Cadila entity is to sell its India-focused Animal Health Business to Multiples Alternate Asset Management-led consortium.

The sale of the business would fetch about Rs2,920 crore on a slump sale basis. As per analysts at Motilal Oswal Financial Services Ltd, the business had sales of Rs600 crore (up 17% YoY) and an EBITDA margin of 25% ( up 800bps YoY) in FY21.

This implies EV/sales of 5times and EV/EBITDA of 19 times. Analysts feel valuations are decent considering its leadership positions across.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA